Abstract: A speech recognition method. The method includes: performing speech activity detection on speech data to obtain multiple speech segments; determining, for each of the speech segments, a number of speakers involved in the each of the speech segments; for each of at least one of the speech segments with the determined number greater than 1: performing speech separation on the each of at least one of the speech segments to obtain multiple audio segments; performing speech recognition on each of the audio segments to obtain respective first speech recognition results for the audio segments; performing feature extraction on each of the audio segments to obtain respective voiceprint feature vectors; and performing clustering on the audio segments with respect to the speakers to obtain a clustering result; and obtaining a second speech recognition result for the speech data based on the clustering result and the respective first speech recognition results.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: The present disclosure provides a domain dictionary constructing method and apparatus, the method including: segmenting a domain corpus sample to obtain a first character segment set, where the first character segment set includes at least one first character segment; calculating an inter-character correlation index of the at least one first character segment; determining a second character segment set according to the correlation index, where the second character segment set includes a first character segment of which the correlation index is greater than or equal to a preset threshold; determining a third character segment set according to the second character segment set, where the third character segment set includes the second character segment set and second character segments of the domain corpus; constructing a domain dictionary according to the third character segment set.

Abstract: An electric drive system with heat management includes an electric drive unit coupled with a battery system and a power conversion system. An energy storage unit contains at least one phase change material and is configured to manage thermal energy. A cooling system is configured to exchange heat and has a fluid system extending through the drive unit, the battery system, the power conversion system, the energy storage unit, and the cooling system. The fluid system configured to collect heat from the drive unit, the battery system and the power conversion system; selectively expel the heat through the cooling system; selectively store the heat in the energy storage unit in the at least one phase change material; and selectively supply heat from the energy storage unit to the battery system.

Abstract: Multi-chip module packaging technologies for GaN and other devices are described. The power module packaging technology described can be applied to all types of medium-voltage devices, such as silicon (Si), silicon carbide (SiC), gallium nitride (GaN), or the latest gallium oxide (Ga2O3) devices. In one example, a power module includes a first substrate, a second substrate, a sintered-silver semiconductor die pillar, the pillar being positioned between the first substrate and the second substrate, a terminal on a first side of the power module, and a terminal on a second side of the power module.

Abstract: Planar, double-side cooled half-bridge power modules using sintered-silver interposers and all sintered-silver joints are described. Thermo-mechanical simulations showed that use of the sintered-silver interposers reduce the thermo-mechanical stresses at vulnerable interfaces as compared to using solid copper interposers. The porous sintered-silver interposers are also easily deformable under a low load, which improves the yield of module interconnections in the presence of imperfections caused by variations in die thickness, interposer height, and substrate distortion. Results on the electrical performance of the modules validate the fabrication approach for the modules, for making high power-density converters with reliable operations at high junction temperatures.

Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles, or WAEVs. These WAEVs can be harnessed to deliver and present viral or bacterial antigens useful for vaccine development; to display homing molecules for targeted delivery of therapeutic molecules to specific cells or tissues; and for packaging and delivery of therapeutic molecules via interactions with the WW domains.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles, or WAEVs for presenting SARS-CoV-2 antigen domains, for example the SARS-CoV-2 M protein, the SARS-CoV-2 E protein, or the SARS-CoV-2 S protein. These WAEVs can be harnessed to deliver and present SARS-CoV-2 antigens useful for vaccine development.

Abstract: Disclosed herein are methods, systems, compositions and strategies for the creation and use WW-domain-Activated Extracellular Vesicles (WAEVs) for presenting HIV antigen domains. These WAEVs can be harnessed to deliver and present HIV antigens useful for vaccine development. Specifically, the disclosure provides a fusion protein comprising: (a) a WW-containing domain; (b) a transmembrane domain; and (c) an extracellular domain, wherein the extracellular domain is an HIV antigen domain. Further provided are sequences of each domain as well as methods of producing and using the fusion protein.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Abstract: Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).

Abstract: Disclosed herein are minimal arrestin domain containing protein 1 (ARRDC1) constructs, which drive the formation of ARRDC1-mediated microvesicles (ARMMs). These vesicles can be harnessed to package and deliver a variety of molecular cargos such as small molecules, nucleic acids, and proteins. An example of such cargo is the genome editor Cas9.

Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: Methods, systems, compositions and strategies for the delivery of RNA into cells in vivo, ex vivo, or in vitro via ARMMs are provided. In some aspects, ARMMs containing fusion proteins of ARRDC1 fused to an RNA binding protein or an RNA binding protein fused to a WW domain are provided. In some aspects, ARMMs containing binding RNAs associated with cargo RNAs are provided. In other aspects, cargo RNAs associated with a binding RNA, such as a TAR element, are loaded into ARMMs via ARRDC1 fusion proteins containing an RNA binding protein, such as trans-activator of transcription (Tat) protein.

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of cargo proteins into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.

Abstract: The invention provide isolated arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicles (ARMMs). Methods for generating and for isolating ARMMs are also provided herein. ARMMs can be used to deliver agents, for example, nucleic acids (e.g., siRNAs, microRNAs, lincRNAs), proteins (e.g., transcription factors, chromatin modulators, kinases, phosphorylases, or recombinases), or small molecules to target cells in vitro and in vivo, and methods for such ARMM-mediated delivery are provided herein. Diagnostic and therapeutic methods using ARMMs are also described herein.

Abstract: Systems, methods, and apparatuses are disclosed for generating mapping data structures based on predicted relationships across tracking data obtained from tracking online browsing histories of users to a network of websites.